Skip to main content
Premium Trial:

Request an Annual Quote

Genomatix Enters CRADA for Prostate Cancer

NEW YORK (GenomeWeb News) – Genomatix today announced that it has entered into a cooperative research and development agreement with the Uniformed Service University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine to extend a collaboration aimed at prostate cancer.

The CRADA is for joint research using definitive genetic markers for the differentiation of patients with a favorable versus poor prognosis at the time of diagnosis and primary treatment.

The CRADA extends a collaboration between Genomatix and the Center for Prostate Disease Research (CPDR) at the Uniformed Service University. The alliance will combine translational research services at CPDR with Genomatix's data analysis expertise "in teasing out novel androgen receptor binding sites in the genome and analyzing prostate cancer metastases using prostate cancer model systems and clinical specimens," the German software analysis firm said in a statement.

"Next-generation sequencing opens a new dimension in biomarker research and will allow a finer grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which also may be targets for therapeutic intervention and treatment monitoring," Thomas Werner, founder of Genomatix, said.

Financial and other terms of the CRADA were not disclosed.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.